Roche, AbbVie get U.S. priority review status for leukemia drug

January 12, 2016 6:07 PM

21 0

Roche, AbbVie get U.S. priority review status for leukemia drug

ZURICH Roche said on Tuesday that the U.S. Food and Drug Administration has granted 'priority review' status for its venetoclax drug for the treatment of a blood cancer, which it is developing with partner AbbVie.

Analysts have said the drug has 'blockbuster' sales potential, meaning sales of more than $1 billion a year, and U.S. regulators had already fast-tracked it for approval last May by designating it a breakthrough therapy.

Also read: Horizon Pharma drug fails key study in rare neuromuscular disease

Read more

To category page

Loading...